Katrien Reynders

Katrien Reynders-Frederix is the former CEO of Pan Cancer T, a biotech developing TCR T-cell therapies for challenging solid tumours, and Board member of Holland Bio, an organisation representing the interests of the dutch biotech. Katrien has a great passion for translating breakthrough science into innovative treatments with commercial potential. Prior Pan Cancer T, she accumulated 20 years of experience in the biopharmaceutical industry from preclinical to market access, where she successfully led international drug development teams and global programs, particularly in the field of immune oncology.